Right-heart failure has long been overshadowed by left-heart failure due to its asymptomatic and well-tolerated nature. However, with improved left-sided therapies and an aging population, RV dysfunction is now a growing concern. Current treatments are limited: tricuspid therapy (applicable in 65% of cases) has restricted feasibility and incomplete efficacy, while surgical off-label blood pumps carry high risks, and percutaneous options offer only temporary relief.
Brightflow is developing the world’s first long-term, percutaneous right ventricular support system. Our pump is implanted directly into the right pulmonary artery via the superior vena cava anastomosis—a proprietary procedure patented by Brightflow and rigorously validated through extensive animal and cadaver studies.
The pump is connected to an internal battery and features no external driveline, eliminating the risk of driveline infections. The internal battery can be recharged transcutaneously via a cochlear plug.
Designed for sustainable performance.
Ensures reduced procedural risks and faster recovery.
Enables safe implantation without open-heart surgery.
Our pump comprises three main components:
The pump is currently under preclinical development – not available for human use.